UTHSC plays key role in COVID vaccine research
About 30 years ago, Michael Whitt, Ph.D., developed what now is a series of surrogate viruses to check the effectiveness of vaccines without having the dangerous ones in the lab.
What Whitt developed allows pharmaceutical companies and labs to test for immune response without using live, dangerous viruses, including SARS-CoV-2, the novel coronavirus.